LLY240913C630000
- 314.95
- 0.000.00%
Eli Lilly and Co Newsroom
Express News | Eli Lilly - in Qwint-2, Efsitora Helped Adults Naïve to Insulin Therapy Currently Using and Not Using GLP-1 Receptor Agonists Achieve an a1C Below 7%
Express News | Once-Weekly Dose of Insulin Efsitora Alfa Delivers a1C Reduction Consistent With the Most Advanced Daily Insulin in People With Type 2 Diabetes
Global Stocks With the Highest Triple Momentum Analysis – BofA
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know
Eli Lilly and Co enters a critical period of expanding diet drug production, welcoming a new CFO.
US pharmaceutical giant Eli Lilly and Co. announced that Lucas Montarce, a senior financial expert within the company, has been appointed as the Chief Financial Officer, and the appointment is effective immediately. This personnel change comes at a critical moment as Eli Lilly is investing billions of dollars to expand production to meet the increasing demand for its diabetes and weight loss drugs (such as Mounjaro and Zepbound). Despite FDA approval, Eli Lilly still faces supply shortages.
A Glimpse Into The Expert Outlook On Eli Lilly Through 28 Analysts
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Eli Lilly (NYSE:LLY) Sheds 6.0% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Is Eli Lilly and Company (LLY) a Good Big Company Stock to Buy Now?
Eli Lilly Price Target Maintained With a $885.00/Share by Cantor Fitzgerald
Eli Lilly Analyst Ratings
Smart Money Is Betting Big In LLY Options
Terns Stock Jumps as Weight Loss Drug Succeeds in Early Trial
Express News | Eli Lilly Shares up 1.7% Premarket After Co Appoints New Finance Chief
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk
Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
Jim Cramer Says Eli Lilly and Company (LLY) Has the Biggest Pharmaceutical Potential
Eli Lilly and Company (LLY): Do Hedge Funds Recommend This Biotech Stock?
Why Big Pharma Is Betting on Telehealth Strategies